Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala

Author(s): Maria Jose, Priyanka Rajmohan*, Joe Thomas, Swathi Krishna, Beena Antony, Unnikrishnan U. Gopinathan, Elsy M. Iyyapan, Raphael M. Porinchu, Ponnu Jose, Lucy Raphael and Praveenlal Kuttichira

Volume 17, Issue 4, 2022

Published on: 18 March, 2022

Page: [327 - 334] Pages: 8

DOI: 10.2174/1574886317666220207120649

Price: $65

Abstract

Background: The reports on adverse experiences following vaccination are scanty from India. It is important to know the real-world post-vaccination experience outside of clinical trial conditions.

Objectives: The study aims to estimate the incidence of adverse events following immunization with the ChAdOx1 nCoV-19 coronavirus vaccine and to identify the predictors for the development of vaccine adverse events.

Methods: A prospective observational study was conducted among health care workers who received the ChAdOx1 nCoV-19 coronavirus vaccine. Study participants were monitored at the site for 30 min following vaccination and were followed up for 7 days after receiving the second dose, with a purpose-specific designed online surveillance form to enquire about any adverse events following vaccination. We used the Chi-squared test for categorical variables and multivariate regression analysis to identify predictors for the development of vaccine adverse effects.

Results: Of 411 participants, the mean age was 30.77 ± 12.5 years and 76.2% were females. Overall, 207 (50.4%) respondents reported at least one post-vaccination symptom receiving either dose of coronavirus vaccination. Fever (34.8%), local pain at the injection site (28.0%), tiredness (25.5%), chills (20%), myalgia (18.7%), headache (17.8%), injection site stiffness (5.4%), joint pain (4.6%) and nausea-vomiting (3.8%) were the most prevalent symptoms following the first dose. Adverse reactions reported after the second dose were milder and less frequent. Postvaccination symptoms were more likely in the younger age group, those with comorbidity particularly, bronchial asthma , and a history of allergy to food/drugs.

Conclusion: All the adverse reactions were of a minor type and non-serious. Side effects were less common in older adults (>60 years). Reactions to the second dose were lesser in intensity and frequency. Younger age, history of allergy, and comorbidities, particularly asthma, were found to be major predictors for the development of adverse events and require more watchful vaccine administration.

Keywords: Adverse events, ChAdOx1 nCoV-19 coronavirus vaccine, Covishield vaccine, adverse drug reaction, COVID-19 vaccine, COVID 19, adverse event following immunization, vaccination.

« Previous Next »
Graphical Abstract

[1]
COVID-19 India. Ministry of health and family welfare government of India. 2021. Available from: https://www.mohfw.gov.in/ (Accessed on 17th November 2021).
[2]
Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine development. Lancet Glob Health 2021; 9(5): e590-2.
[http://dx.doi.org/10.1016/S2214-109X(21)00043-7] [PMID: 33667404]
[3]
Callaway E. The race for coronavirus vaccines: A graphical guide. Nature 2020; 580(7805): 576-7.
[http://dx.doi.org/10.1038/d41586-020-01221-y] [PMID: 32346146]
[4]
Herve C, Laupeze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines 2019; 4: 39.
[http://dx.doi.org/10.1038/s41541-019-0132-6]
[5]
Product information. ChAdOx1 nCoV-19 corona virus vaccine (Recombinant). 2021. Available from: https://www.seruminstitute.com/pdf/covishield_ChAdOx1_nCoV19_corona_virus_vaccine_insert (Accessed on 7th February 2021).
[6]
Ramasamy MN, Minassian AM, Ewer KJ, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396(10267): 1979-93.
[http://dx.doi.org/10.1016/S0140-6736(20)32466-1] [PMID: 33220855]
[7]
Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[8]
Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011; 73(7): 598-603.
[http://dx.doi.org/10.1097/PSY.0b013e3182294a50] [PMID: 21862825]
[9]
Jayadevan R, Shenoy R, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.08.21251366]
[10]
Sah R, Shrestha S, Mehta R, et al. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Med Infect Dis 2021; 40: 101989.
[http://dx.doi.org/10.1016/j.tmaid.2021.101989] [PMID: 33578045]
[11]
Valsan N, Thomas R, Kuttichira P, Valsan C, James A. Willingness and psychological preparedness to attend to COVID-19 patients among healthcare workers in a tertiary care private hospital in Kerala - A mixed-method study. Kerala J Psychiatry 2020; 33(2): 96-104.
[http://dx.doi.org/10.30834/KJP.33.2.2020.204]
[12]
Joshi RK, Muralidharan CG, Gulati DS, et al. Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Med J Armed Forces India 2021; 77(Suppl. 2): S505-7.
[http://dx.doi.org/10.1016/j.mjafi.2021.05.011] [PMID: 34334920]
[13]
Remlabeevi A, Mathew T, Nair GSH, Rajasekharan Nair GL, Alex MR. Adverse events and their association with comorbidities after first and second doses of Covishield vaccination among healthcare workers of Government owned medical colleges in Kerala. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.05.19.21257317v1.1]
[14]
Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine 2021; 38: 101038.
[http://dx.doi.org/10.1016/j.eclinm.2021.101038] [PMID: 34505032]
[15]
Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med 2021; 19(1): 173.
[http://dx.doi.org/10.1186/s12916-021-02059-5] [PMID: 34315454]
[16]
Chen J, Cai Y, Chen Y, Williams AP, Gao Y, Zeng J. Nervous and muscular adverse events after covid-19 vaccination: A systematic review and meta-analysis of clinical trials. Vaccines (Basel) 2021; 9(8): 939.
[http://dx.doi.org/10.3390/vaccines9080939] [PMID: 34452064]
[17]
Chen JS, Alfajaro MM, Chow RD, et al. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J Virol 2021; 95(7): e00014-21.
[http://dx.doi.org/10.1128/JVI.00014-21] [PMID: 33441348]
[18]
Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother 2016; 12(9): 2391-402.
[http://dx.doi.org/10.1080/21645515.2016.1183077] [PMID: 27246296]
[19]
Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27(2): 225-8.
[http://dx.doi.org/10.1038/s41591-020-1124-9] [PMID: 33082575]
[20]
Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(10): 667-8.
[http://dx.doi.org/10.1038/d41573-020-00151-8] [PMID: 32887942]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy